Nafila Al Riyami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nafila Al Riyami has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Fahad Zadjali
Oman College of Health Sciences, P.O box 3720, 112, Muscat, Oman
2 shared publications - Qatiba Al Farai
Department of Clinical Biochemistry, Sultan Qaboos, University Hospital, University Medical City, P.O box 35, 123, Muscat, Oman
2 shared publications - Abdullah Mohammed Al Alawi
Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman
1 shared publication - Ali Al Khamyasi
Department of Clinical Biochemistry, Sultan Qaboos, University Hospital, University Medical City, P.O box 35, 123, Muscat, Oman
1 shared publication - Anuradha Ganesh
Department of Ophthalmology, Sultan Qaboos University, Muscat, Oman
1 shared publication - Badriya Al-Alawi
Clinical Biochemistry Program, Oman Medical Specialty Board, Muscat 123, Oman
1 shared publication
Latest Publications
- Open Access
- 10 March 2026
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 49, e00524
Comparison of conventional formulas and machine learning models for estimating serum low-density lipoprotein cholesterol
- 10 March 2026
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 49, e00524
Open AccessComparison of conventional formulas and machine learning models for estimating serum low-density lipoprotein cholesterol
- Open Access
- 4 October 2023
- Published by Wiley in International Journal of Endocrinology
- Vol. 2023, 1-6
Incidence of Dysmagnesemia among Medically Hospitalized Patients and Associated Clinical Characteristics: A Prospective Cohort Study
Background. Magnesium (Mg) disorders are common among hospitalized patients and are linked to poor health outcomes. We aimed to determine the incidence of dysmagnesemia among medically hospitalized patients and to identify factors that are associated with dysmagnesemia. Methods. A prospective cohort study was conducted at Sultan Qaboos University Hospital (SQUH) from April 1st, 2022, to October 31st, 2022, and involved hospitalized adult patients (≥18 years) under the care of the general internal medicine unit. The patients’ serum total magnesium (Mg) concentrations were categorized as hypomagnesemia (≤0.69 mmol/L), hypermagnesemia (≥1.01 mmol/L), or dysmagnesemia, which encompassed either hypomagnesemia or hypermagnesemia. Results. Of the 304 patients evaluated, dysmagnesemia was observed in 22.0%, which comprised of 17.4% with hypomagnesemia and 4.6% with hypermagnesemia. Statistically significant associations were identified between hypermagnesemia and chronic kidney disease (CKD) ( = 0.05) and elevated creatinine levels ( < 0.01) and lower estimated glomerular filtration rate (eGFR) ( < 0.01). Hypomagnesemia was linked to lower ionized calcium ( = 0.03) and admission due to infectious diseases ( = 0.02). However, ordered regression analysis did not find any significant associations with the different magnesium groups. Conclusion. Dysmagnesemia was prevalent among hospitalized patients and was associated with different factors; however, ordered regression analysis did not find any association with the different magnesium group, probably due to the limited number of included individuals.
- 4 October 2023
- Published by Wiley in International Journal of Endocrinology
- Vol. 2023, 1-6
Open AccessIncidence of Dysmagnesemia among Medically Hospitalized Patients and Associated Clinical Characteristics: A Prospective Cohort Study
Background. Magnesium (Mg) disorders are common among hospitalized patients and are linked to poor health outcomes. We aimed to determine the incidence of dysmagnesemia among medically hospitalized patients and to identify factors that are associated with dysmagnesemia. Methods. A prospective cohort study was conducted at Sultan Qaboos University Hospital (SQUH) from April 1st, 2022, to October 31st, 2022, and involved hospitalized adult patients (≥18 years) under the care of the general internal medicine unit. The patients’ serum total magnesium (Mg) concentrations were categorized as hypomagnesemia (≤0.69 mmol/L), hypermagnesemia (≥1.01 mmol/L), or dysmagnesemia, which encompassed either hypomagnesemia or hypermagnesemia. Results. Of the 304 patients evaluated, dysmagnesemia was observed in 22.0%, which comprised of 17.4% with hypomagnesemia and 4.6% with hypermagnesemia. Statistically significant associations were identified between hypermagnesemia and chronic kidney disease (CKD) ( = 0.05) and elevated creatinine levels ( < 0.01) and lower estimated glomerular filtration rate (eGFR) ( < 0.01). Hypomagnesemia was linked to lower ionized calcium ( = 0.03) and admission due to infectious diseases ( = 0.02). However, ordered regression analysis did not find any significant associations with the different magnesium groups. Conclusion. Dysmagnesemia was prevalent among hospitalized patients and was associated with different factors; however, ordered regression analysis did not find any association with the different magnesium group, probably due to the limited number of included individuals.
- Open Access
Mucolipidosis Type IV in Omani Families with a Novel MCOLN1 Mutation: Search for Evidence of Founder Effect
Mucolipidosis Type IV (MLIV) is caused by a deficiency of the mucolipin cation channel encoded by Mucolipin TRP Cation Channel 1 gene (MCOLN1). It is a slowly progressive neurodevelopmental and neurodegenerative disorder causing severe psychomotor developmental delay and progressive visual impairment, which is often misdiagnosed as cerebral palsy. We describe six patients with MLIV from two Omani families with a novel c.237+5G>A mutation in the MCOLN1 gene predicted to affect mRNA splicing. Mutation screening with a high-resolution melting (HRM) assay in a large population sample did not detect this mutation in control subjects. This report highlights the importance of considering MLIV in the differential diagnosis of patients in a pediatric age group with cerebral palsy-like presentation. Although the same rare mutation was seen in two apparently unrelated families, this was not seen in the sample screened from the general population. The HRM assay provides a cost-effective assay for population screening for the c.237+5G>A mutation.
Open AccessMucolipidosis Type IV in Omani Families with a Novel MCOLN1 Mutation: Search for Evidence of Founder Effect
Mucolipidosis Type IV (MLIV) is caused by a deficiency of the mucolipin cation channel encoded by Mucolipin TRP Cation Channel 1 gene (MCOLN1). It is a slowly progressive neurodevelopmental and neurodegenerative disorder causing severe psychomotor developmental delay and progressive visual impairment, which is often misdiagnosed as cerebral palsy. We describe six patients with MLIV from two Omani families with a novel c.237+5G>A mutation in the MCOLN1 gene predicted to affect mRNA splicing. Mutation screening with a high-resolution melting (HRM) assay in a large population sample did not detect this mutation in control subjects. This report highlights the importance of considering MLIV in the differential diagnosis of patients in a pediatric age group with cerebral palsy-like presentation. Although the same rare mutation was seen in two apparently unrelated families, this was not seen in the sample screened from the general population. The HRM assay provides a cost-effective assay for population screening for the c.237+5G>A mutation.